CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Dabrafenibdrug
Likely dose
Dabrafenib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01682213
NCT01682213Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 10, 2012·Updated May 26, 2020

In Brief

A Phase 2 clinical trial evaluating Dabrafenib for Melanoma. Completed, enrolled 23 participants across 1 site.

Detailed Summary

In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network, Novartis

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2012
Enrollment StartSep 1, 2012
Primary CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 13.8 years ago

Interventions

Dabrafenibdrug

Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.